We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$117M
AUM Growth
+$850K
Cap. Flow
+$4.42M
Cap. Flow %
3.78%
Top 10 Hldgs %
62.08%
Holding
41
New
3
Increased
8
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$4.99M
2
RXRX icon
Recursion Pharmaceuticals
RXRX
+$4.47M
3
RBRK icon
Rubrik
RBRK
+$1.2M
4
TRML
Tourmaline Bio
TRML
+$1.01M
5
KYMR icon
Kymera Therapeutics
KYMR
+$903K

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$5.35M
2
EXAI
Exscientia Plc American Depositary Shares
EXAI
+$4.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$760K
4
ONC
BeOne Medicines Ltd
ONC
+$618K
5
INCY icon
Incyte
INCY
+$499K

Sector Composition

Rank Sector Weight
1 Healthcare 98.3%
2 Technology 1.36%
3 Materials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRDA icon
26
Entrada Therapeutics
TRDA
$267M
$849K 0.73%
49,082
– –
RVMD icon
27
Revolution Medicines
RVMD
$44B
$842K 0.72%
19,253
+11,953
+164% +$603K
CLYM
28
Climb Bio
CLYM
$804M
$835K 0.71%
463,654
– –
RANI icon
29
Rani Therapeutics
RANI
$89M
$676K 0.58%
493,584
– –
BOLT icon
30
Bolt Biotherapeutics
BOLT
$7.78M
$624K 0.53%
58,348
– –
BSLK
31
DELISTED
Bolt Projects Holdings
BSLK
$391K 0.33%
40,598
– –
ARGX icon
32
argenx
ARGX
$54.1B
$264K 0.23%
430
– –
DBVT
33
DBV Technologies
DBVT
$847M
$115K 0.1%
37,095
– –
ALXO icon
34
ALX Oncology
ALXO
$290M
$70.1K 0.06%
41,950
– –
AFMD
35
DELISTED
Affimed
AFMD
$44.3K 0.04%
37,247
– –
JBIO
36
Jade Biosciences
JBIO
$1.34B
– –
-1,370
Closed -$100K
BMRN icon
37
BioMarin Pharmaceuticals
BMRN
$12.4B
– –
-10,815
Closed -$760K
RARE icon
38
Ultragenyx Pharmaceutical
RARE
$2.55B
– –
-3,820
Closed -$212K
SWTX
39
DELISTED
SpringWorks Therapeutics
SWTX
– –
-7,450
Closed -$239K
EXAI
40
DELISTED
Exscientia Plc American Depositary Shares
EXAI
– –
-859,892
Closed -$4.2M
LBPH
41
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-160,570
Closed -$5.35M
1
2

Similar funds

MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
MW
Merited Wealth North Bay Village, Florida $121M AUM

Nan Fung Group Holdings's Q4 2024 Portfolio in Review

As of Q4 2024, Nan Fung Group Holdings held 41 positions worth $117M, up 0.73% from $116M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Nan Fung Group Holdings deployed $4.42M of net new capital in Q4 2024, opening 3 new positions and adding to 8 existing holdings. Its largest new stake was Verona Pharma: 133,040 shares worth $6.18M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Technology and Materials.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $618K trimmed.

  • Nan Fung Group Holdings's largest Q4 2024 buy was Verona Pharma: 133,040 shares worth $6.18M.
  • Nan Fung Group Holdings added most to Tourmaline Bio in Q4 2024, an estimated $1.01M increase.
  • Nan Fung Group Holdings's biggest Q4 2024 reduction was BeOne Medicines Ltd, cutting an estimated $618K.
  • Nan Fung Group Holdings fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $5.35M.
  • Nan Fung Group Holdings's ten largest holdings make up 62% of its $117M portfolio in Q4 2024.
  • Nan Fung Group Holdings opened 3 new positions and closed 6 in Q4 2024.
  • Nan Fung Group Holdings's portfolio value rose 0.73% quarter-over-quarter to $117M.

Based on Nan Fung Group Holdings's 13F filing for Q4 2024, filed 13 Feb 2025.